CCL27抗体;CCL27 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CCL27 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using CCL27 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CCL27 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of A431 cells using CCL27 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectal cancer tissues using CCL27 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach cancer tissues using CCL27 mouse mAb with DAB staining.    

  
  

CCL27. also known as cutaneous T-cell-attracting chemokine (CTACK), is a small chemokine belonging to the CC subfamily. It is primarily produced by keratinocytes in the skin and interacts with the CCR10 receptor, playing a critical role in immune surveillance and inflammatory responses. CCL27 facilitates the recruitment of CCR10-expressing T cells, particularly memory T lymphocytes, to cutaneous sites, making it essential for maintaining skin-specific immune homeostasis. Its expression is upregulated under inflammatory conditions, such as atopic dermatitis, psoriasis, and allergic contact dermatitis, implicating it in the pathogenesis of chronic skin disorders. Additionally, CCL27 has been linked to tumor immunity, as aberrant expression is observed in cutaneous T-cell lymphoma and melanoma.

CCL27 antibodies are immunological tools designed to detect or neutralize CCL27 protein activity. Polyclonal and monoclonal antibodies against CCL27 are widely used in research to study its biological functions, including ligand-receptor interactions, immune cell trafficking, and inflammatory signaling pathways. These antibodies enable techniques like ELISA, Western blotting, immunohistochemistry, and flow cytometry to quantify CCL27 levels in tissues or fluids, map its distribution, and assess its role in disease models. Neutralizing antibodies, in particular, are employed to block CCL27/CCR10 signaling in experimental settings, providing insights into therapeutic targeting for inflammatory skin diseases or cancer. The development and validation of CCL27 antibodies continue to support advances in dermatology, immunology, and oncology research.